ZURICH, March 21 (Reuters) - Lonza Group (LONN.S) said on Monday it signed a manufacturing agreement with Sweden's Oasmia Pharmaceutical (OASM.ST) for ovarian cancer drug candidate Cantrixil that was licensed by Oasmia from the Australian pharmaceutical company Kazia last year.
SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1), a clinical-stage, first-in-class drug candidate under development for the treatment of ovarian cancer.
Oasmia Pharmaceutical, an innovation-focused specialty pharmaceutical company, is set to acquire exclusive global development rights for Kazia Therapeutics’ ovarian cancer drug candidate Cantrixil in a $44 million deal.
Uppsala, Sweden, June 8, 2020 – Oasmia Pharmaceutical AB has partnered with the Swiss Group for Clinical Cancer Research (SAKK) to conduct the first clinical trial of Oasmia’s docetaxel micellar compound in advanced prostate cancer. Prostate cancer in men is a significant health problem worldwide and is a leading cause of cancer death in men. Oasmia’s docetaxel micellar formulation uses Oasmia’s proprietary solubility technology platform enabling the intravenous administration of water-insoluble compounds without traditional solubility enhancers. Oasmia’s solubility technology platform has been utilized in another product, Apealea®, which has obtained Marketing Authorization in the EU in 2018, in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive ovarian cancer.
Uppsala, Sweden, May 14, 2020 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces that data collected from the Company’s development program of docecal, a solvent-free nanoparticle micellar formulation of docetaxel have been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Annual meeting taking place between May 29 -June 02, 2020.
Uppsala, Sweden, May 13, 2020. Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announced the outcome of a strategic review assessing all aspects of the business to maximise the company’s resources, to achieve the full potential of its XR17 platform technology and to optimise Oasmia’s path towards long-term, profitable growth.
On March 25, 2020 Oasmia Pharmaceutical AB and US based Elevar Therapeutics Inc. signed a global strategic partnership deal regarding the commercialization of Oasmia’s anticancer product Apealea®. The agreement included a USD 20 million upfront payment which Oasmia now has received.